The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating north of 80 as they begin their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Is Arvinas Stock A Buy?
Arvinas stock recently reclaimed its 50-day and 200-day moving averages, a good sign. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the biotech stock is able to establish and enter a buy zone in heavy volume.
The biotech firm showed 0% EPS growth in the latest quarterly report, while sales growth came in at -22%. Keep an eye out for the company's next round of numbers on or around Aug. 6.
Arvinas stock earns the No. 217 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and UnitedTherapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
